Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

The fight against type 2 diabetes just reached a groundbreaking milestone. Last week, the U.S. Food and Drug Administration ...

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

随着2024年这些突破性临床试验的相继发表，GLP-1类药物展现出远超预期的治疗潜力。从最初的糖尿病治疗，到减重管理，再到阿尔茨海默病、心血管疾病、慢性肾病、骨关节炎、多囊卵巢综合征等多个重大疾病领域，这类药物正在重新定义现代医学的治疗范式。特别值得 ...

This may start to bring down the cost of brand-name competitors—here's who might get access, and one major difference from ...

(Nasdaq:LEXX)(Nasdaq:LEXXW), a global innovator in drug delivery platforms, has announced the engagement of a contract ...

Hims & Hers' robust Q3 2024 performance, driven by a 44% increase in subscribers and 77% y/y revenue growth, underscores its ...

India's biopharma sector marked notable achievements, with approvals of key biosimilars and the launch of advanced CAR-T ...